Indeed, the 15% rate of TMR in the present study is approximately twice the rate of dissociated response observed in patients with NSCLC receiving single-agent anti-PD1/PDL1 therapy (8%).5 We recognize the limitations of comparing our current findings with studies using different definitions of response heterogeneity, as the case for this immune checkpoint inhibitor-treated population. The gene discussed is CD274; the disease is non-small cell lung carcinoma.